No Detail Found!

Applications and Challenges of CRISPER/Cas-9 System in Cancer Therapy

Author(s)
Ahmad Jalal Masood Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
Ejaz Ahmed Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
Rimsha Iftikhar Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
Laiba Javed Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
Aimen Sahar Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
Muhammad Hossain Department of Pharmacy, Quaidi-Azam University, Islamabad, Pakistan.
Abstract
This review article is aimed at providing an outline of the present information base available on the applications of CRISPR/Cas9 in cancer therapy and the challenges raised by its implementation. We will first explain the mechanism of action and other key components pertaining to the functioning of CRISPR/Cas9 technology. Further, we will provide case studies that have had some success in pre-clinical and clinical applications of CRISPR/Cas9. However, there are several challenges that prevent the wide application of this very promising approach of CRISPR/Cas9 in cancer therapy. Among them are off-target effects and unintended mutations, difficulties in delivery, targeting specificity, etc. Specificity enhancement, improvement in delivery systems, and solutions against regulatory challenges have been described.
Publication Details
Page(s) 10-28
Published Journal: Global Pharmaceutical Sciences Review, Volume: 9, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
Challenges, genome, Applications, genome engineering, CRISPER/Cas9, Recombinant DNA Technology
References
Pickar-Oliver A.,Gersbach C. A. .2019 .The next generation of CRISPR-Cas technologies and applications. Nature Reviews Molecular Cell Biology, 20(8) : 490-507.
Mengstie M. A.,Azezew M. T.,Dejenie T. A.,Teshome A. A.,Admasu F. T.,Teklemariam A. B.,Mulu A. T.,Agidew M. M.,Adugna D. G.,Geremew H.,Abebe E. C. .2023 .Recent advancements in reducing the OffTarget effect of CRISPR-CAS9 genome editing. Biologics, 18 : 21-28.
Crudele J. M.,Chamberlain J. S. .2018 .Cas9 immunity creates challenges for CRISPR gene editing therapies. Nature Communications, 9(1) : .
Stefanoudakis D.,Kathuria-Prakash N.,Sun A. W.,Abel M.,Drolen C. E.,Ashbaugh C.,Zhang S.,Hui G.,Tabatabaei Y. A.,Zektser Y.,Lopez L. P.,Pantuck A.,Drakaki A. .1813 .The Potential Revolution of Cancer Treatment with CRISPR Technology. , 15(6) : .
Doudna J. A.,Charpentier E. .2014 .The new frontier of genome engineering with CRISPR-Cas9. , 346(6213) : .
Stadtmauer E. A.,Fraietta J. A.,Davis M. M.,Cohen A. D.,Weber K. L.,Lancaster E.,Mangan P. A.,Kulikovskaya I.,Gupta M.,Chen F.,Tian L.,Gonzalez V. E.,Xu J.,Jung I.,Melenhorst J. J.,Plesa G.,Shea J.,Matlawski T.,Cervini A.,June C. H. .2020 .CRISPR-engineered T cells in patients with refractory cancer. Science, 367(6481) : .
Martinez-Lage M.,Puig-Serra P.,Menendez P.,Torres-Ruiz R.,Rodriguez-Perales S. .2018 .CRISPR/CAS9 for cancer therapy: Hopes and challenges. Biomedicines, 6(4) : .
Khoshandam M.,Soltaninejad H.,Mousazadeh M.,Hamidieh A. A.,Hosseinkhani S. .2023 .Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine. Genes & Diseases, 02(1) : 268-282.
Rasul M. F.,Hussen B. M.,Salihi A.,Ismael B. S.,Jalal P. J.,Zanichelli A.,Jamali E.,Baniahmad A.,Ghafouri-Fard S.,Basiri A.,Taheri M. .2022 .Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. Molecular Cancer, 21(1) : .
Hsu P. D.,Lander E. S.,Zhang F. .2014 .Development and applications of CRISPR-CAS9 for genome engineering. Cell, 05(6) : 1262-1278.
Roy P. S.,Saikia B. J. .2016 .Cancer and cure: A critical analysis. Indian Journal of Cancer, 53(3) : 0019-509x.
Wang H.,La Russa,Qi M.,L. S. M. .2016 .CRISPR/CAS9 in genome editing and beyond. Annual Review of Biochemistry, 060815(1) : 227-264.
Zhang J.,Adikaram P.,Pandey M.,Genis A.,Simonds W. F. .2016 .Optimization of genome editing through CRISPR-Cas9 engineering. , 7(3) : 166-174.
0

Citations

0

Downloads

47

Views